NCT06380153

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Patients With Renal Impairment

To Evaluate the Pharmacokinetics of Hemay005 Tablets in Subjects With Mild and Moderate Renal Impairment and Normal Renal Function After a Single Oral Administration

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 26 (actual)
• Sponsor: Ganzhou Hemay Pharmaceutical Co., Ltd · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Accepted

Summary

The aim of this study was to evaluate the pharmacokinetics of Hemay005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment.

Detailed description

To evaluate the pharmacokinetics and safety of Hemay 005 tablets in subjects with mild to moderate renal impairment and normal renal function, and to provide a basis for the formulation of clinical medication regimens for patients with renal impairment.

Conditions

• Psoriasis

Interventions

Type	Name	Description
DRUG	Hemay005	15mg/tablet，Four tablets (60mg) each time. Participants will receive a single dose of Hemay005 tablet in Day1

Timeline

• Start date: 2024-05-07
• Primary completion: 2025-04-16
• Completion: 2025-04-16
• First posted: 2024-04-23
• Last updated: 2025-12-04

Locations

1 site across 1 country: China